Cover Image
市場調查報告書

醫藥品安全監視的全球市場 - 臨床實驗階段(臨床前研究,第一階段,第二階段,第三階段,第四階段「上市後監測」)及實施機關(公司內部,外部委託機關)產業分析、規模、市場佔有率、成長率、趨勢及預測

Pharmacovigilance Market and Service Providers - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

出版商 Transparency Market Research 商品編碼 296695
出版日期 內容資訊 英文 159 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品安全監視的全球市場 - 臨床實驗階段(臨床前研究,第一階段,第二階段,第三階段,第四階段「上市後監測」)及實施機關(公司內部,外部委託機關)產業分析、規模、市場佔有率、成長率、趨勢及預測 Pharmacovigilance Market and Service Providers - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
出版日期: 2014年02月28日 內容資訊: 英文 159 Pages
簡介

強化以提供患者藥劑資訊為中心的法規及監察體制及其緊急性增加了其對醫藥品安全監視相關市場的成長,由於急性、慢性病患的增加造成醫藥品消費擴大這個結果,伴隨而來了許多副作用及藥物中毒的傷害案例。此外,受到這些藥物事件被媒體炒熱的影響,製藥企業不得不利用許多外部機構來對應藥劑的安全問題。

本報告以這樣的醫藥品安全監督市場為焦點,分就實驗階段、手法、服務提供機關及區別來分析、驗証其趨勢及背景及今後的演變,再彙整活躍於該市場上的主要企業簡介,為您概述為以下內容。

第1章 簡介

  • 報告的內容說明
  • 調查方法
  • 市場區隔

第2章 摘要整理

第3章 醫藥品安全監視的全球市場動態

  • 簡介
    • 推動要素
      • 藥物消費數量的增加
      • 關係到重度障礙和死亡的藥物中毒事件屢次發生
      • 採用減輕風險的新技術
      • 醫藥品安全監視服務委託外部機關之勢擴大
      • 隨著製造轉移到低成本地區,藥物開發的全球化
    • 阻礙因素
      • 嚴格且多方面的法規批審
    • 課題
      • 熟練人員的不足
    • 波特的五力分析:醫藥品安全監視的全球市場
    • 醫藥品安全監視的全球市場向心力分析 - 各地區

第4章 醫藥品安全監視的全球市場 - 各臨床實驗階段

  • 概要
    • 臨床前研究
    • 第一期臨床試驗
    • 第二期臨床試驗
    • 第三期臨床試驗
    • 第四階段臨床實驗(上市後監測)

第5章 醫藥品安全監視的全球市場 - 手法別

  • 概要
    • 自發報告
    • 標的報告
    • kohoto調查
    • 電子病歷調查
    • 強化ADR(醫藥品副作用)報告

第6章 醫藥品安全監視的全球市場 - 服務提供機關別

  • 概要
    • 公司內部
    • 外部委託

第7章 醫藥品安全監視的全球市場 - 各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第8章 醫藥品安全監視的全球市場 - 市場佔有率分析

  • 主要各企業的市場佔有率

第9章 建議

  • 成功策略
    • 與臨床研究委外機構和生命科學產業受託機關的策略性合作·聯盟的開發
    • 針對藥物安全性優化的中心輻射模式
    • 針對成果改善的強化業務活動
    • 新興國家的市場發展

第10章 企業簡介(概要,財務,產品系列,產業策略等)

圖表一覽

目錄

A rising tide of regulatory expectations, tougher inspection regime and instant need of patient reporting has provided the much needed impetus for the growth of the pharmacovigilance market. An upsurge in number of acute and chronic diseases has consequently led to a rise in number of drug consumption, which has also elicited a growth in the number of adverse drug events and drug toxicity cases. Moreover, several high-profile safety issues, regulatory warnings, large volume of events to be reviewed along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services. There are two major outsourcing services opted by these pharmaceutical players i.e. traditional CROs and BPOs. These outsourcing services not only provide cost savings but also helps in bringing process efficiency. Pharmaceutical companies are now forming long term partnership with the CROs and BPOs to share the costs involved in PV process right from drug discovery to post marketing approvals. In addition, PV requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting.

The research report on pharmacovigilance provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of pharmacovigilance market on the bases of clinical trials phases i.e. Phase I to III and post marketing surveillance (PMS). We have also mapped the trend for preference of the pharmaceutical players for in-house and outsourcing in our chapter by type of service.

The global pharmacovigilance market has been segmented based on all the above mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in term of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has also been provided along with market size estimations.

The report exclusively studies the aforementioned segments with respect to geography. Under geographic section we have covered four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (ROW).

The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global pharmacovigilance market. The section also covers opportunities and market attractiveness analysis of the geographical regions.

The report concludes with the competitive landscape and company profiles of major market players. These market players have been profiled on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Some of the major players profiled in this report include PRA International Inc., Covance Inc., Synowledge LLC, OptumInsight Inc., iMedGlobal, TCS, iGATE Corporation, Cognizant Technology Solutions, Quintiles and others.

Table of Contents

Chapter 1 Introduction

  • 1.1 Report Description
  • 1.2 Research Methodology
  • 1.3 Market Segmentation

Chapter 2 Executive Summary

Chapter 3 Global Pharmacovigilance Market Dynamics

  • 3.1 Introduction
    • 3.1.1 Drivers
      • 3.1.1.1 Rise in number of drug consumption
      • 3.1.1.2 Rise in drug toxicity cases producing significant morbidity and mortality
      • 3.1.1.3 Embracing new technologies to mitigate risk
      • 3.1.1.4 Rise in adoption of pharmacovigilance outsourcing services
      • 3.1.1.5 Globalization of drug development with shift from manufacturing activities from high cost to low cost regions
    • 3.1.2 Restraints
      • 3.1.2.1 Stringent and varied regulatory approval processes
    • 3.1.3 Challenges
      • 3.1.3.1 Lack of availability of skilled labor
  • 3.2 Porter's Five Force Analysis: Global Pharmacovigilance Market
    • 3.2.1 Bargaining Power of Suppliers
    • 3.2.2 Bargaining Power of Buyers
    • 3.2.3 Threat of New Entrants
    • 3.2.4 Threat of Substitutes
    • 3.2.5 Competitive Rivalry
  • 3.3 Market Attractiveness Analysis of the Global Pharmacovigilance Market, by Geography
    • 3.3.1 Market Attractiveness Analysis: Global Pharmacovigilance Market, 2012, by Geography

Chapter 4 Global Pharmacovigilance Market, by Clinical Trial Phases

  • 4.1 Overview
    • 4.1.1 Preclinical Studies
      • 4.1.1.1 Global Preclinical Studies Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
    • 4.1.2 Phase I trial
      • 4.1.2.1 Global Clinical Trial Phase I Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
    • 4.1.3 Phase II trial
      • 4.1.3.1 Global Clinical Trial Phase II Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
    • 4.1.4 Phase III trial
      • 4.1.4.1 Global Clinical Trial Phase III Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
    • 4.1.5 Phase IV trial (Post marketing surveillance)
      • 4.1.5.1 Global Clinical Trial Phase IV Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)

Chapter 5 Global Pharmacovigilance Market, By Type of Methods

  • 5.1 Overview
    • 5.1.1 Spontaneous Reporting
      • 5.1.1.1 Global Spontaneous Drug Safety Reporting Market Revenue, 2011 - 2019 (USD Million)
    • 5.1.2 Targeted Reporting
      • 5.1.2.1 Global Targeted Drug Safety Reporting Market Revenue, 2011 - 2019 (USD Million)
    • 5.1.3 Cohort Event Monitoring
      • 5.1.3.1 Global Cohort Event Monitoring Market Revenue, 2011 - 2019 (USD Million)
    • 5.1.4 EHR Monitoring
      • 5.1.4.1 Global Electronic Health Records (EHR) Monitoring Market Revenue, 2011 - 2019 (USD Million)
    • 5.1.5 Intensified ADR Reporting
      • 5.1.5.1 Global Intensified ADR Reporting Market Revenue, 2011 - 2019 (USD Million)

Chapter 6 Global Pharmacovigilance Market, by Type of Service Providers

  • 6.1 Overview
    • 6.1.1 In-House
      • 6.1.1.1 Global In-House Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
    • 6.1.2 Contract Outsourcing
      • 6.1.2.1 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)

Chapter 7 Global Pharmacovigilance Market, by Geography

  • 7.1 Overview
    • 7.1.1 Comparative Analysis: Global Pharmacovigilance Market, by Geography, 2012 & 2019 (Value %)
  • 7.2 North America
    • 7.2.1 North America Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • 7.3 Europe
    • 7.3.1 Europe Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Asia-Pacific Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • 7.5 Rest of the World
    • 7.5.1 Rest of the World Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)

Chapter 8 Global Pharmacovigilance Market Share Analysis

  • 8.1 Market Share Analysis by Key Players of Global Pharmacovigilance Market
    • 8.1.1 Global CRO Market Share Analysis, by Key Players, 2012 (%)

Chapter 9 Recommendations

  • 9.1 Success Strategies
    • 9.1.1 Developing Strategic Alliances and Partnerships With CROs and Life Science BPOs Companies
    • 9.1.2 Hub and Spoke model to optimize drug safety
    • 9.1.3 Enhancing operational activities for better outcomes
    • 9.1.4 Expand Market into Emerging Countries

Chapter 10 Company Profiles

  • 10.1 Accenture, Plc
    • 10.1.1 Company Overview
    • 10.1.2 Financial Overview
    • 10.1.3 Product Portfolio
    • 10.1.4 Business Strategies
    • 10.1.4.1 Mergers and acquisitions
    • 10.1.5 Recent Developments
  • 10.2 Bristol-Myers Squibb
    • 10.2.1 Company Profile
    • 10.2.2 Financial overview
    • 10.2.3 Product Portfolio
    • 10.2.4 Business Strategies
      • 10.2.4.1 Strategic collaboration
      • 10.2.4.2 Research and Development Initiatives
      • 10.2.4.3 Recent Developments
  • 10.3 Clinquest Group B.V.
    • 10.3.1 Company Overview
    • 10.3.2 Product Portfolio
    • 10.3.3 Business Strategies
      • 10.3.3.1 Strategic partnership
    • 10.3.4 Recent Developments
  • 10.4 Cognizant Technology Solutions
    • 10.4.1 Company Overview
    • 10.4.2 Financial Overview
    • 10.4.3 Product Portfolio
    • 10.4.4 Business Strategies
      • 10.4.4.1 Expansion of geographical footprint
      • 10.4.4.2 Expansion of product portfolio
      • 10.4.4.3 Highly-skilled manpower
      • 10.4.4.4 Strategic acquisitions
    • 10.4.5 Recent Developments
  • 10.5 Covance, Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Financial Overview
    • 10.5.3 Product Portfolio
    • 10.5.4 Business Strategies
      • 10.5.4.1 New product development and innovation
      • 10.5.4.2 Agreements and collaborations
      • 10.5.4.3 Strategic acquisitions
      • 10.5.4.4 Geographical expansion of business
    • 10.5.5 Recent Developments
  • 10.6 GlaxoSmithKline (GSK)
    • 10.6.1 Company Overview
    • 10.6.2 Financial overview
    • 10.6.3 Product Portfolio
    • 10.6.4 Business strategies
      • 10.6.4.1 Research and development initiatives
      • 10.6.4.2 Direct to Consumer Advertising
      • 10.6.4.3 Mergers and acquisitions
    • 10.6.5 Recent developments
  • 10.7 ICON, Plc
    • 10.7.1 Company Overview
    • 10.7.2 Financial Overview
    • 10.7.3 Product Portfolio
    • 10.7.4 Business Strategies
      • 10.7.4.1 Business expansion in APAC region
      • 10.7.4.2 Expansion of services offered
    • 10.7.5 Recent Developments
  • 10.8 iGATE Corporation
    • 10.8.1 Company Overview
    • 10.8.2 Financial Overview
    • 10.8.3 Product Portfolio
    • 10.8.4 Business Strategies
      • 10.8.4.1 Strategic Acquisition
    • 10.8.5 Recent Developments
  • 10.9 iMEDGlobal Corporation
    • 10.9.1 Company Overview
    • 10.9.2 Product Portfolio
    • 10.9.3 Business Strategies
      • 10.9.3.1 Geographical Expansion
    • 10.9.4 Recent Developments
  • 10.10 Infosys
    • 10.10.1 Company Overview
    • 10.10.2 Financial Overview
    • 10.10.3 Product Portfolio
    • 10.10.4 Business Strategies
      • 10.10.4.1 Extensive product portfolio
      • 10.10.4.2 Geographical expansion of business
    • 10.10.5 Recent Developments
  • 10.11 inVentiv Health Inc.
    • 10.11.1 Company Overview
    • 10.11.2 Product Portfolio
    • 10.11.3 Business Strategies
      • 10.11.3.1 Strategic Partnership
      • 10.11.3.2 Strategic Acquisition
    • 10.11.4 Recent Developments
  • 10.12 Johnson and Johnson
    • 10.12.1 Company Profile
    • 10.12.2 Financial Overview
    • 10.12.3 Product Portfolio
    • 10.12.4 Business Strategies
      • 10.12.4.1 Extensive Research and Development Investments
      • 10.12.4.2 Strategic Collaborative Arrangements
      • 10.12.4.3 Recent Developments
  • 10.13 Novartis International AG
    • 10.13.1 Company Overview
    • 10.13.2 Financial Overview
    • 10.13.3 Product Portfolio
    • 10.13.4 Business Strategy
      • 10.13.4.1 Mergers and Acquisitions
    • 10.13.5 Recent Developments
  • 10.14 OptumInsight, Inc.
    • 10.14.1 Company Overview
    • 10.14.2 Product Portfolio
    • 10.14.3 Business Strategies
      • 10.14.3.1 Strategic product launch
      • 10.14.3.2 Strategic collaboration
    • 10.14.4 Recent Developments
  • 10.15 Parexel International Corporation
    • 10.15.1 Company Overview
    • 10.15.2 Financial Overview
    • 10.15.3 Product Portfolio
      • 10.15.3.1 Strong presence in Asia and emerging markets
      • 10.15.3.2 Strategic alliances
      • 10.15.3.3 Mergers & Acquisitions
    • 10.15.4 Recent Developments
  • 10.16 Pfizer, Inc.
    • 10.16.1 Company Overview
    • 10.16.2 Financial Overview
    • 10.16.3 Product Portfolio
    • 10.16.4 Business Strategies
      • 10.16.4.1 Acquisitions
    • 10.16.5 Recent Developments
  • 10.17 Pharmaceutical Product Development, Inc. (PPD, Inc.)
    • 10.17.1 Company Overview
    • 10.17.2 Product Portfolio
    • 10.17.3 Business Strategies
      • 10.17.3.1 Expanding geographic presence
      • 10.17.3.2 Incorporation of innovative technologies
      • 10.17.3.3 Strategic acquisitions
      • 10.17.3.4 New product launch and innovation
    • 10.17.4 Recent Developments
  • 10.18 PRA International, Inc.
    • 10.18.1 Company Overview
    • 10.18.2 Product Portfolio
    • 10.18.3 Business Strategies
      • 10.18.3.1 Mergers and acquisitions
    • 10.18.4 Recent Developments
  • 10.19 Quantum Solutions India
    • 10.19.1 Company Overview
    • 10.19.2 Product Portfolio
    • 10.19.3 Business Strategies
      • 10.19.3.1 Strategic Collaborations
  • 10.20 Quintiles Transnational Corporation
    • 10.20.1 Company Overview
    • 10.20.2 Financial Overview
    • 10.20.3 Product Portfolio
    • 10.20.4 Business Strategies
      • 10.20.4.1 Expansion of services
      • 10.20.4.2 Acquisitions and partnerships
      • 10.20.4.3 Innovation in services offered
    • 10.20.5 Recent Developments
  • 10.21 F. Hoffmann-La Roche Ltd.
    • 10.21.1 Company Overview
    • 10.21.2 Financial Overview
    • 10.21.3 Product Portfolio
    • 10.21.4 Business Strategies
      • 10.21.4.1 Licensing Agreement
      • 10.21.4.2 Product portfolio expansion
  • 10.22 Sanofi Aventis
    • 10.22.1 Company Overview
    • 10.22.2 Financial Overview
    • 10.22.3 Product Portfolio
    • 10.22.4 Business Strategy
      • 10.22.4.1 Renewal of cooperation protocol
      • 10.22.4.2 Recent developments
  • 10.23 Synowledge LLC
    • 10.23.1 Company Overview
    • 10.23.2 Product Portfolio
    • 10.23.3 Business Strategies
      • 10.23.3.1 Geographical Expansion
      • 10.23.3.2 Strategic Partnership
    • 10.23.4 Recent Developments
  • 10.24 United BioSource Corporation
    • 10.24.1 Company Overview
    • 10.24.2 Product Profiling
    • 10.24.3 Business Strategies
      • 10.24.3.1 Strategic acquisitions
  • 10.25 Wipro Limited
    • 10.25.1 Company Overview
    • 10.25.2 Financial Overview
    • 10.25.3 Product Portfolio
    • 10.25.4 Business Strategies
      • 10.25.4.1 Geographical expansion

List of Figures

  • FIG. 1 Drug Safety From Molecule to Market
  • FIG. 2 Global Pharmacovigilance : Market Segmentation
  • FIG. 3 Global Pharmacovigilance Market, by Type of Service Providers, 2012 (USD Million)
  • FIG. 4 Global Pharmacovigilance Market, by Type of Clinical Trial Phases, 2012 (USD Million)
  • FIG. 5 Global Pharmacovigilance Market, by Type of Methods, 2012 (USD Million)
  • FIG. 6 Global Pharmacovigilance Market: Drivers and Restraints
  • FIG. 7 Porter's Five Force Analysis: Global Pharmacovigilance Market
  • FIG. 8 Market Attractiveness Analysis: Global Pharmacovigilance Market, 2012, by Geography
  • FIG. 9 Safety Services : Product Lifecycle
  • FIG. 10 Global Preclinical Studies Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 11 Global Clinical Trial Phase I Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 12 Global Clinical Trial Phase II Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 13 Global Clinical Trial Phase III Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 14 Global Clinical Trial Phase IV Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 15 Comparison of Methods: Pharmacovigilance reporting
  • FIG. 16 Global Spontaneous Drug Safety Reporting Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 17 Global Targeted Drug Safety Reporting Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 18 Global Cohort Event Monitoring Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 19 Global Electronic Health Records (HER) Monitoring Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 20 Global Intensified ADR Reporting Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 21 End-to-End Safety Across the Lifecycle
  • FIG. 22 Global In-House Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 23 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 24 Comparative Analysis: Global Pharmacovigilance Market, by Geography, 2012 & 2019 (Value %)
  • FIG. 25 North America Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 26 Europe Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 27 Asia-Pacific Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 28 Rest of the World Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 29 Global CRO: Market Share, by Key Players, 2012 (%)
  • FIG. 30 Accenture, Plc.: Annual Revenue (USD Billion) 2010 - 2012
  • FIG. 31 Bristol-Myers Squibb: annual sales revenue, USD million, 2010 - 2012
  • FIG. 32 Cognizant Technology Solutions: Annual Sales Revenue, USD Million (2010- 2012)
  • FIG. 33 COVANCE, Inc.: Annual Sales Revenue, USD Billion (2010- 2012)
  • FIG. 34 GSK, Annual Sales Revenue, 2010 - 2012 (USD million) (Conversion rate: 1 GBP = 1.6651 USD)
  • FIG. 35 ICON, PLC: Annual Sales Revenue, USD Million (2010- 2012)
  • FIG. 36 iGATE Corporation, Annual Revenue: 2010 - 2012 (USD Million)
  • FIG. 37 Infosys: Annual Sales Revenue, USD Million (2010- 2012)
  • FIG. 38 Johnson and Johnson: annual sales revenue, USD million, 2010 - 2012
  • FIG. 39 Novartis International AG., Annual Sales: 2010 - 2012 (USD Million)
  • FIG. 40 Parexel International Corporation: Annual Sales Revenue, USD Million (2010- 2012)
  • FIG. 41 Pfizer, Inc.: Annual Revenue, 2010 - 2012 (USD Million)
  • FIG. 42 Quintiles Transnational Corporation: Annual Sales Revenue, USD Billion (2010- 2012)
  • FIG. 43 F. Hoffmann-La Roche Ltd., Annual Revenue: 2010 - 2012 (USD Million) (1 CHF = 1.09 USD)
  • FIG. 44 Sanofi: Annual Sales Revenue, 2010 - 2012 (USD million)
  • FIG. 45 Wipro Limited: Annual Revenue (USD Million) 2010 - 2012

List of Tables

  • TABLE 1 Market Snapshot : Pharmacovigilance Market
  • TABLE 2 List of Drugs Withdrawn Recently:
  • TABLE 3 Global Pharmacovigilance Market Revenue, By Type of Clinical Trial Phases, 2011 - 2019 (USD Million)
  • TABLE 4 Global Pharmacovigilance Market Revenue, By Type of Methods, 2011 - 2019 (USD Million)
  • TABLE 5 Global Pharmacovigilance Market Revenue, By Type of Service Providers, 2011 - 2019 (USD Million)
  • TABLE 6 Global Pharmacovigilance Market Revenue, By Geography, 2011 - 2019 (USD Million)
Back to Top